319 related articles for article (PubMed ID: 1522358)
1. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):161-72. PubMed ID: 1522358
[TBL] [Abstract][Full Text] [Related]
2. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
[TBL] [Abstract][Full Text] [Related]
3. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Dec; 59(4):558-68. PubMed ID: 1802938
[TBL] [Abstract][Full Text] [Related]
4. Studies on risk of leprosy relapses in China: relapses after treatment with dapsone monotherapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):371-8. PubMed ID: 10700910
[TBL] [Abstract][Full Text] [Related]
5. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
Kar HK; Sharma P
Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
[TBL] [Abstract][Full Text] [Related]
6. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
7. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):436-44. PubMed ID: 1474282
[TBL] [Abstract][Full Text] [Related]
8. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
Dasananjali K; Schreuder PA; Pirayavaraporn C
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
[TBL] [Abstract][Full Text] [Related]
9. Rate of relapse in multibacillary patients after cessation of long-course dapsone monotherapy supplemented by a final supervised single dose of 1500 mg of rifampin.
Cartel JL; Naudin JC
Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):215-9. PubMed ID: 8046260
[TBL] [Abstract][Full Text] [Related]
10. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.
Becx-Bleumink M; Berhe D
Int J Lepr Other Mycobact Dis; 1992 Jun; 60(2):173-84. PubMed ID: 1522359
[TBL] [Abstract][Full Text] [Related]
11. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era.
Smith TC; Richardus JH
Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):353-8. PubMed ID: 7525795
[TBL] [Abstract][Full Text] [Related]
12. Risk of relapse in leprosy. The Leprosy Unit, WHO.
Indian J Lepr; 1995; 67(1):13-26. PubMed ID: 7622926
[TBL] [Abstract][Full Text] [Related]
13. Relapse rate and incidence of dapsone resistance in lepromatous leprosy patients in Addis Ababa: risk factors and effect of short-term supplementary treatment.
Warndorff van Diepen T; Mengistu G
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):189-97. PubMed ID: 2410520
[TBL] [Abstract][Full Text] [Related]
14. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
Biswas S; Mondal KK
Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
[TBL] [Abstract][Full Text] [Related]
15. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
Chen XS; Li WZ; Jiang C; Ye GY
Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
[TBL] [Abstract][Full Text] [Related]
16. Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy--a comparison of methods based mainly on skin smears as opposed to clinical methods--alternative clinical methods for classification of patients.
Becx-Bleumink M
Int J Lepr Other Mycobact Dis; 1991 Jun; 59(2):292-303. PubMed ID: 2071986
[TBL] [Abstract][Full Text] [Related]
17. Relapses after a single dose of rifampin in skin-smear negative multibacillary patients after dapsone monotherapy.
Jamet P; Blanc L; Fayne OC; Traore I; Bobin P
Int J Lepr Other Mycobact Dis; 1994 Jun; 62(2):209-14. PubMed ID: 8046259
[TBL] [Abstract][Full Text] [Related]
18. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
[TBL] [Abstract][Full Text] [Related]
20. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
